159 related articles for article (PubMed ID: 9492254)
21. Combinations of protease inhibitors.
TreatmentUpdate; 1998 Apr; 10(2):1-3. PubMed ID: 11365433
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
23. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
[TBL] [Abstract][Full Text] [Related]
24. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
25. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
[No Abstract] [Full Text] [Related]
26. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection.
Misson J; Clark W; Kendall MJ
J Clin Pharm Ther; 1997 Apr; 22(2):109-17. PubMed ID: 9373809
[TBL] [Abstract][Full Text] [Related]
27. What they say about protease inhibitors.
Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522
[TBL] [Abstract][Full Text] [Related]
28. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
29. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
30. What they say about: protease inhibitors.
Posit Aware; 2000; 11(1):48-54. PubMed ID: 11366351
[TBL] [Abstract][Full Text] [Related]
31. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
Salmon-Céron D; Deleuze J; Coste J; Guerin C; Ginsburg C; Blanche P; Finkielsztejn L; Pecqueux L; Chaput S; Gorin I; Sicard D
Ann Med Interne (Paris); 2000 Jun; 151(4):297-302. PubMed ID: 10922958
[TBL] [Abstract][Full Text] [Related]
32. Saquinavir/low-dose ritonavir: its use in HIV infection.
Johnson M; Peters B
AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107
[TBL] [Abstract][Full Text] [Related]
33. A review of low-dose ritonavir in protease inhibitor combination therapy.
Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
[TBL] [Abstract][Full Text] [Related]
34. Drug interaction potential with inhibitors of HIV protease.
Van Cleef GF; Fisher EJ; Polk RE
Pharmacotherapy; 1997; 17(4):774-8. PubMed ID: 9250556
[TBL] [Abstract][Full Text] [Related]
35. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
36. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
37. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
38. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.
Valer L; De Mendoza C; De Requena DG; Labarga P; García-Henarejos A; Barreiro P; Guerrero F; Vergara A; Soriano V;
AIDS; 2002 Sep; 16(14):1964-6. PubMed ID: 12351959
[No Abstract] [Full Text] [Related]
39. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
40. [HIV protease inhibitors].
Rubio R; Romeu J; Viciana P; Redondo C
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():10-4. PubMed ID: 9053020
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]